XORTX Therapeutics Announces Successful Funding Round
CALGARY, Alberta – In a significant development, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has successfully closed a funding round amounting to US$1.1 million through a registered direct offering. This initiative was initially made public on October 21, and it has attracted institutional interest resulting in the purchase of 1,750,000 common shares of the company at a price of US$0.63 per share.
Details of the Offering
The offering included a strategic agreement with one institutional investor. As part of this arrangement, XORTX has issued 572,470 common shares and 1,117,530 pre-funded warrants. Each warrant allows the holder to acquire a common share at a minimal exercise price of $0.001 per share.
Use of Proceeds from the Offering
The gross revenue generated from this offering, totaling US$1,102,500.00, will be essential for XORTX. The company plans to allocate these funds primarily toward working capital and general commercial needs, which are crucial for advancing its pharmaceutical projects.
Role of Placement Agents
D. Boral Capital LLC played a pivotal role as the sole placement agent for this offering, acquiring 87,500 agent warrants. The agent warrants can be exercised for one common share at US$0.69, becoming available to holders starting 181 days after issuance, and will have a tenure of eighteen months from the closing date.
Company's Clinical Development
XORTX Therapeutics is actively engaged in clinical studies focused on pivotal programs that target common medical conditions such as gout and progressive kidney disease. Their lead product, XRx-026, aims specifically at treating gout, while additional projects include XRx-008 for autosomal dominant polycystic kidney disease (ADPKD) and XRx-101, which addresses acute kidney injury linked to respiratory infections.
Innovations in Treatment
What sets XORTX apart is its commitment to innovate treatments that hinder the production of uric acid, a key player in gout pathology. The development of XRx-225, a pre-clinical program aimed at Type 2 diabetic nephropathy, further reflects the company's vision to target issues that significantly affect quality of life.
Understanding the Impact of These Treatments
The ongoing research and development initiatives position XORTX to make substantial contributions to healthcare, specifically for individuals suffering from chronic conditions like gout and kidney disease. The company's dedication to these areas demonstrates its mission to improve patient outcomes through scientific advancement.
Extended Company Information
For those interested in learning more about XORTX and its innovative products, detailed information can be found on their official website. The company is proud to continue its journey in therapeutic development, grounded in scientific evidence and patient-centric approaches.
Contact Information
Patients, investors, and interested parties may reach out to the company’s representatives for more information. Allen Davidoff, the CEO, can be contacted via email or directly through the company's communication lines. Nick Rigopulos, the Director of Communications, is also available for inquiries regarding corporate developments.
Frequently Asked Questions
What is the purpose of the recent funding announced by XORTX?
The recent US$1.1 million funding will be used primarily for working capital and general corporate purposes.
How many shares were offered in the recent direct offering by XORTX?
XORTX offered 1,750,000 common shares in its recent registered direct offering.
What are the main therapeutic areas XORTX focuses on?
XORTX primarily focuses on developing therapies for gout, progressive kidney disease, and related conditions.
Who acted as the placement agent for the offering?
D. Boral Capital LLC acted as the sole placement agent for this offering.
What innovations are being developed by XORTX?
Innovative products include XRx-026 for gout and XRx-008 for ADPKD, alongside other therapeutic programs targeting kidney health.
